Skip to content

Effect of Abhraka Bhasma Amrutikarana in type 2 diabetes

Pharmaceutical standardization and comparative clinical efficacy of Abhraka Bhasma (with and without Amrutikarana) in the management of Type 2 Diabetes (Madhumeha)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031095
Enrollment
102
Registered
2021-02-08
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Abhraka Bhasma with Amrutikarana: In treatment group patients will be treated with 1 tablet (187.5mg Abhraka Bhasma with Amrutikarana + 62.5mg Triphala Ghana) twice a day 15 min. before

Sponsors

Institute for Post Graduate Teaching and Research in Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Either the sexes having age between 18 to 60 years. Patients having chief & associated complains of Madhumeha (Prabhuta-Avilamutrata, pipashadhikya, kshudhadhikya etc.) Patients with stable continuous dose of modern medicine for more than 1 month. Known patient of Type 2 Diabetes and also the preliminarily diagnosed patients on the basis of signs and symptoms of the disease are confirmed by FBS and PPBS.

Exclusion criteria

Exclusion criteria: Age more than 60 and below18 years Prameha pidika (Diabetic nonhealing wound), Systemic infection, active infection other than superficial mild skin infestation Secondary Diabetes mellitus and Diabetes mellitus Type 1 Patients of any other severe illness. Malignant and accelerated hypertensive. Other chronic debilitating diseases. Pregnant woman and expecting conception (within six month) Lactating mothers. Patients with fatal diabetic complication like end stage renal disease Patient with diabetic ketoacidosis Severe anaemia below 7gm% Hb.

Design outcomes

Primary

MeasureTime frame
Control in blood sugar level and symptomatic reliefTimepoint: 2 months

Secondary

MeasureTime frame
Improved quality of lifeTimepoint: 2 months

Countries

India

Contacts

Public ContactDr Prashant Bedarkar

ITRA Gujarat Ayurved University Jamnagar

drprashantbedarkar@gmail.com9316876572

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026